United States / Canada / Australia / New Zealand / /
Currency
USD / /
Facility
Public Policy Studies University of Chicago November / National Institute of Aging / Institute of Medicine / /
IndustryTerm
pharmaceutical and medical device producers / medical technologies / pharmaceutical and medical device manufacturers / individual technologies / pharmaceutical industry / particular medical technology / medical technology assessments / reimbursement systems / health insurance experiment / health systems / medical technology assessment / non-dictatorial allocation algorithm / formal technology assessment / important tool / technology assessment / medical technology / /
MedicalCondition
cancers / cancer / both serious illness / cervical cancer / illness / /
Organization
Congress / U.S. Preventive Services Task Force / National Institute of Health / Graduate School / Department of Medicine / National Institutes of Health / Food and Drug Administration / Department of Economics / University of Chicago / Institute of Medicine / Robert Wood Johnson Foundation / Public Health Service / National Institute of Aging / Olin Foundation / Lasker Foundation / Medicare / /
Person
Thamer / McClellan / Cutler / Harold Varmus / Perry / Remler / Joseph Newhouse / David Meltzer / /
Position
AUTHOR / Director / /
PublishedMedium
the New England Journal of Medicine / /
Technology
non-dictatorial allocation algorithm / particular medical technology / specific medical technologies / /
DRAFT: NOT FOR CITATION WITHOUT APPROVAL OF THE AUTHOR Can Medical Cost-Effectiveness Analysis Identify the Value of Research? David Meltzer M.D., Ph.D.